Black Diamond Therapeutics, Inc.BDTXEarnings & Financial Report
Nasdaq
NextMar 31, 2026
BDTX Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-11.0M
Net Profit
$-8.5M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.15
Black Diamond Therapeutics, Inc. Q3 2025 Financial Summary
Black Diamond Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-8.5M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-8.5M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $70.0M | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | $142.5M | $150.0M | $137.9M | $176.2M | $166.4M | $157.7M |
| Liabilities | $38.2M | $39.0M | $40.5M | $34.7M | $33.8M | $31.6M |
| Equity | $104.3M | $111.0M | $97.4M | $141.5M | $132.6M | $126.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-21.2M | $-14.7M | $-11.3M | $53.4M | $-9.2M | $-7.8M |